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CtBP1 Is Expressed in Melanoma and Represses the
Transcription of p16INK4a and Brca1
Hui Deng1,2,3,5, Jing Liu1,5, Yu Deng1,5, Gangwen Han2, Yiqun G. Shellman1, Steven E. Robinson4,
John J. Tentler4, William A. Robinson4, David A. Norris1, Xiao-Jing Wang2 and Qinghong Zhang1,2
Carboxyl-terminal binding protein 1 (CtBP1) has been shown to suppress the transcription of several tumor
suppressors in vitro. Paradoxically, a previous report showed that CtBP1 mRNA was downregulated in melanoma.
Using immunostaining, we found that a large percentage of human melanomas were positive for CtBP1 protein.
Furthermore, we demonstrated that CtBP1 expression in melanoma cells contributes to cell proliferation and
genome instability, two aspects promoting melanoma initiation and progression. Breast cancer susceptibility gene
1 (Brca1), a core protein in DNA-damage repair, was repressed by CtBP1 in melanoma cells. Consistently, Brca1
loss in human malignant melanoma tissues was found to be inversely correlated with CtBP1 expression levels. In
addition, the inhibitor of cyclin-dependent protein kinases (CDKs), p16INK4a, whose loss has been related to the
pathogenesis of melanoma, was repressed by CtBP1 as well. Our findings suggest an important role of CtBP1 in
the transcriptional control of p16INK4a and Brca1, with CtBP1 overexpression potentially contributing to
increased proliferation and DNA damage in melanoma.
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INTRODUCTION
Melanoma is the most fatal form of skin cancer (Hall et al.,
1999). One in 50 Americans has a lifetime risk of developing
melanoma. In 2009, nearly 63,000 were diagnosed with
melanoma in the United States, resulting in B8,650 deaths.
The projected numbers by the National Cancer Institute for
2012 are even higher with 76,250 diagnoses and 9,180
deaths predicted (http://www.cancer.gov/cancertopics/types/
melanoma). Identification of the molecules and pathways
responsible for melanoma is critical to the rational develop-
ment of effective preventive and therapeutic strategies.
Multiple genetic events have been related to the pathogen-
esis of melanoma (Pho et al., 2006; MacKie et al., 2009). The
multiple tumor suppressor 1 (CDKN2A/MTS1) gene encodes
an inhibitor of cyclin-dependent protein kinases (CDKs),
p16INK4a, which has been localized to 9p21, a region
linked to familial melanoma and homozygously deleted in
many tumor cell lines and sporadic primary melanomas
(Cannon-Albright et al., 1994a, b; Hussussian et al., 1994;
Kumar et al., 1999). The DNA-damage repair pathway
involving Brca2 (breast cancer susceptibility gene 2) has
been implicated in melanoma development as well (BCLC,
1999); however, to what extent the genetic alterations of
Brca2 and Brca1 genes contribute to melanoma is contro-
versial (Kadouri et al., 2009). Besides genetic mutation,
transcriptional and translational alterations in response to
environmental risk factors play important roles in melanoma
development. Specifically, p16INK4a has been shown to be
repressed by Id1 in early melanomas (Polsky et al., 2001).
Whether Brca1 expression is transcriptionally or translatio-
nally altered in melanoma has not been studied.
Carboxyl-terminal binding protein 1 (CtBP1) is a transcrip-
tional corepressor that often represses tumor-suppressor genes.
Previously, we found CtBP1 overexpression in 80% of head
and neck cancers (Deng et al., 2010) and more than 90% of
invasive ductal breast cancers (Deng et al., 2012). In contrast,
CtBP1 mRNA has been reported to be downregulated in
melanoma (Poser et al., 2002), yet the protein level of CtBP1
has not been assessed in melanoma samples. In this report, we
examined protein expression levels of this corepressor in
melanoma tissue samples and studied the potential
contribution of CtBP1-mediated transcription in melanoma
cell proliferation and defective DNA repair.
RESULTS
Previous investigation has presented data to indicate the loss
of CtBP1 mRNA during melanoma progression (Poser et al.,
2002), but the expression of CtBP1 protein in melanoma was
ORIGINAL ARTICLE
1Department of Dermatology, University of Colorado, Denver, Aurora, Colorado,
USA; 2Department of Pathology, University of Colorado, Denver, Aurora,
Colorado, USA; 3Department of Dermatology, The Sixth People’s Hospital of
Shanghai, Shanghai Jiaotong University, Shanghai, China and 4Department of
Medicine, University of Colorado, Denver, Aurora, Colorado, USA
Correspondence: Xiao-Jing Wang, Department of Pathology, University of
Colorado, Denver, Aurora, Colorado 80045, USA.
E-mail: xj.wang@UCDenver.edu or Qinghong Zhang, Department of
Dermatology, University of Colorado, Denver, Aurora, Colorado 80045, USA.
E-mail: Qinghong.Zhang@UCDenver.edu
5Co-first authors.
Received 11 June 2012; revised 25 September 2012; accepted 23 October
2012; published online 10 January 2013
Abbreviations: Brca1, breast cancer susceptibility gene 1; CDK, cyclin-
dependent protein kinase; ChIP, chromatin immunoprecipitation; CtBP1,
Carboxyl-terminal binding protein 1; MMC, mitomycin C; siRNA, small
interfering RNA; siCtBP1, siRNA targeting CtBP1
1294 Journal of Investigative Dermatology (2013), Volume 133 & 2013 The Society for Investigative Dermatology
unknown. Therefore, we performed western blotting of
different grades of melanoma cell lines (radial, vertical, and
metastatic) and normal melanocytes. CtBP1 was detected in
normal melanocytes and melanoma lines, yet higher CtBP1
expression was found in metastatic melanoma lines such as
A375 and WM852 cells (Supplementary Figure S1 online). To
examine the role of CtBP1 in melanoma, we stained a
human melanoma tissue array with an anti-CtBP1
antibody (http://www.millipore.com/catalogue/item/07-306),
which recognizes the highly conserved carboxyl-terminus of
CtBP1. The specificity of the anti-CtBP1 antibody was
confirmed by the lack of staining in CtBP1 / mouse
embryonic fibroblasts compared with the strong nuclear
signal detected by this antibody in CtBP1-positive cells
(Figure 1a). To test the sensitivity of this antibody, we knocked
down CtBP1 in the CtBP1-containing melanoma cell line
A375 using two small interfering RNAs (siRNAs) and per-
formed immunofluorescence staining. Positive nuclear stain-
ing was readily detected in A375 cells, whereas the signal was
largely attenuated in the siCtBP1 (siRNA targeting CtBP1)-
treated A375 cells (Figures 2c and 3c). We concluded that this
antibody can be used to assess human CtBP1 expression.
Therefore, we performed CtBP1 immunohistochemical study
on the melanoma tissue arrays (ME1003, Biomax), which
contain 21 cases of melanocyte-derived nevi, 56 cases of
malignant melanoma lesions, and 20 cases of metastases.
Positive nuclear CtBP1 staining was found in a large percen-
tage of nevi, malignant melanoma, and metastasis cases
(Figure 1b; Supplementary Table S1 online). Figure 1c displays
representative cases of CtBP1 staining in malignant mela-
noma. In contrast, CtBP1 staining was rarely detected in
normal skin (Supplementary Figure S2 online). Further patho-
logical study shows that CtBP1 overexpression was detected in
11/21 (52%) of benign nevocellular nevi and 39/49 (80%) of
stage I–II malignant melanoma cases (Figure 1b), suggesting
that CtBP1 overexpression is an early event in melanoma
development.
CtBP1 is a transcriptional corepressor of multiple tumor
suppressors (Chinnadurai, 2009); its transcriptional regulation
is context specific and highly dependent on the presence of
transcriptional repressors that directly interact with the target
genes (Chinnadurai, 2002). p16INK4a is a well-known tumor
suppressor for melanoma that plays an important role in cell
cycle progression (Kumar et al., 1999; Krimpenfort et al.,
2001; Yang et al., 2001). We asked whether CtBP1 in
melanoma could also affect p16INK4a expression as it has
been shown to be a CtBP1 target in fibroblasts and
keratinocytes (Mroz et al., 2008). To explore the
transcriptional regulation role of CtBP1 in melanoma, we
performed chromatin immunoprecipitation (ChIP) assays in
melanoma cell lines. CtBP1 was recruited to the p16INK4a
promoter in WM852 (data not shown) and A375 cells
(Figure 2a). Furthermore, we found that CtBP1 binding to
the p16INK4a promoter confers transcriptional repression of
Figure 1. Carboxyl-terminal binding protein 1 (CtBP1) overexpression in
human melanoma tissues. (a) Specificity of the anti-CtBP1 antibody was
evaluated in immunofluorescence assays using the CtBP1 / versus the
CtBP1-rescued (CtBP1þ ) mouse embryonic fibroblasts (MEFs). Bar¼5mm. (b)
CtBP1 overexpression is an early event in melanoma. Melanoma cases with
positive CtBP1 staining were reported as a percentage of the total cases for the
different pathological and clinical stages. (c) Human melanoma tissue array
was stained for CtBP1. The Vector Red Alkaline Phosphatase Substrate Kit 1
was used in the immunohistochemical development. (c, left panels) CtBP1-
negative (CtBP1( )) melanoma samples and (c, right panels) CtBP1-positive
(CtBP1(þ )) melanoma samples. Melanin presence was observed as dark
brown patchy staining (lower left panel). Bar¼ 40mm.
CtBP1 staining
CtBP1+
Number of CtBP1-positive cases/total cases
Benign nevocellular nevi 11/21 (52%)
Malignant melanoma 43/56 (77%)
Metastasis 14/20 (70%)
Tumor stage
Stage I, II 39/49 (80%)
Stage III, IV 4/7 (57%)
Node status
N0  
a
b
c
39/49 (80%)
N+ 4/7 (57%)
Metastasis status
M0 41/54 (76%)
M+ 2/2 (100%)
CtBP1 (–) with melanin
CtBP1–
CtBP1 staining
CtBP1 (–) CtBP1 (+)
CtBP1 (+)
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the p16INK4a gene, as CtBP1 knockdown using two different
siRNAs increased p16INK4a mRNA level in A375 cells
(Figure 2b).
To assess whether CtBP1 knockdown restores p16INK4a
protein expression, we performed immunofluorescent staining
of p16INK4a in A375 cells and A375 cells treated with siRNAs
to CtBP1 (Figure 2c). Consistent with the mRNA increase, the
nuclear p16INK4a staining was upregulated when CtBP1 was
knocked down (Figure 2c). As restoration of p16INK4a
expression would inhibit CDKs, thus decreasing cell prolifera-
tion, we examined the growth of A375 cells and A375 cells
treated with siRNAs of CtBP1. Under normal conditions, A375
cells grow exponentially and double their number daily. After
48 hours, cell numbers quadrupled; in contrast, A375 cells
with CtBP1 knockdown for 48 hours exhibited significantly
reduced growth (Figure 2d). These data suggest that CtBP1-
mediated p16INK4a repression abrogates p16INK4a functions,
thus contributing to proliferation in melanoma.
To determine whether CtBP1 represses p16INK4a expres-
sion in clinical samples, we performed immunohistochemistry
for CtBP1 and p16INK4a using a tissue array (ME1003,
Biomax), focusing on the malignant melanoma lesions
(n¼ 56) for the larger sample size compared with the nevi
(n¼ 21) and the metastatic samples (n¼20) on this tissue
array (Figure 2e). Consistent with the reported p16INK4a loss
in melanoma (Jonsson et al., 2010), p16INK4a loss was
detected in 35/56 (62.5%) malignant melanoma samples;
among them, 76.7% (33/43) cases associated with positive
CtBP1 staining whereas only 15.4% (2/13) cases of p16INK4a
loss associated with negative CtBP1 staining. The inverse
correlation of p16INK4a and CtBP1 (P¼0.0001) in
melanoma tissues is consistent with the repression of the
melanoma tumor suppressor p16INK4a by CtBP1.
Genomic instability is a hallmark of melanoma develop-
ment, and DNA-damage repair defect is a major contributor.
Therefore, we investigated the role of CtBP1 in melanoma
DNA-damage repair. Previously, we demonstrated that Brca1
was under transcriptional control by CtBP1 in head and neck
squamous cell carcinoma (Deng et al., 2010). Later, CtBP1
was also found to repress Brca1 in breast cancer cells (Di
et al., 2010; Deng et al., 2012). Even though Brca1 mutation
has not been associated with melanoma susceptibility, Brca1
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Figure 2. Carboxyl-terminal binding protein 1 (CtBP1) represses p16INK4a expression in melanoma cells. (a) CtBP1 binding to the p16INK4a promoter.
**Po0.01 versus IgG. (b) CtBP1 knockdown (siCtBP1-1 and siCtBP1-2) increased p16INK4a mRNA. (c) Nuclear p16INK4a staining was significantly increased by
CtBP1 knockdown in A375 cells. Bar¼5mm. (d) CtBP1 knockdown decreases proliferation of A375 cells. (e) Correlation between CtBP1 upregulation and
p16INK4a downregulation in a human melanoma tissue array (US Biomax, ME1003). Note that top panels show a lesion with negative CtBP1 but positive
p16INK4a staining (p16INK4a(þ )CtBP1( )). In contrast, a lesion with CtBP1 nuclear staining showed negative staining for p16INK4a in the consecutive section
(lower panels, p16INK4a( )CtBP1(þ )). Bar¼ 40mm. P¼ 0.0001 between CtBP1 (þ ) and CtBP1 ( ) groups, calculated by Fisher’s exact test.
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downregulation may contribute to melanoma development
through decreased DNA-damage repair. Hence, we asked
whether CtBP1 represses the tumor suppressor Brca1 in
melanoma cells. First, we assessed whether CtBP1 was
recruited to the Brca1 gene to repress transcription in
melanoma cells. We performed ChIP assays and found that
CtBP1 bound to the Brca1 gene promoter in WM852 (data not
shown) and A375 cells (Figure 3a). To examine whether the
CtBP1 binding to Brca1 promoter confers transcriptional
repression to the Brca1 gene in melanoma cell lines, we used
two different siRNAs to knock down CtBP1 and assayed the
expression of Brca1 mRNA in A375 cells. Consistent with the
increased Brca1 transcription observed with siCtBP1 treatment
in HNSCC cells, Brca1 mRNA levels increased 4–5-fold when
CtBP1 was abrogated in A375 cells (Figure 3b).
To further assess whether restoration of Brca1 expression by
CtBP1 knockdown in A375 cells rescues Brca1 at the func-
tional level, we examined Brca1-mediated DNA-repair foci
formation by immunofluorescence staining using the A375
cells and A375-siCtBP1 cells treated with mitomycin C
(MMC). Both siRNAs against CtBP1 knocked down CtBP1
effectively (Figure 3c). Brca1 translocates to sites of MMC-
induced DNA damage with other members of the Fanc/Brca
pathway to form DNA-repair nuclear foci (D’Andrea and
Grompe, 2003). Only B10% of A375 cells were able to
form Brca1 foci, whereas A375 cells with siCtBP1 knockdown
for 48 hours exhibited a 3-fold increase in the number of cells
able to form MMC-induced DNA-repair foci, from 11.6±1.2
to 40.3±3.1 and 35.7±1.2 per 100 cells (Figure 3c). These
data suggest that CtBP1-mediated Brca1 repression abrogates
Brca1 functions and results in fewer DNA-repair foci in human
melanoma cells.
To further investigate the repression of Brca1 by CtBP1, we
adopted the melanoma xenograft model using A375 mela-
noma cells. After the melanoma xenografts were established,
siRNAs against CtBP1 were delivered in vivo to A375
xenografts for 2 weeks. After the knockdown of CtBP1 in the
xenografts, the expression of Brca1 was upregulated
(Figure 3d). We performed comet assays using tumor cells
from the xenografts. DNA breaks were significantly reduced
when CtBP1 was knocked down, from 11.3±2.1 to 4.3±0.6
and 5.3±0.6 per 100 cells (Figure 3e).
We next studied the relative expression of Brca1 and CtBP1
in melanoma cases for the potential nongenetic Brca1 loss,
which contributes to melanoma genomic instability
(Figure 4a). Brca1 loss was detected in 33/56 (58.9%) of
malignant melanomas. Moreover, we found Brca1 loss
strongly correlated with CtBP1 overexpression: 72.1% (31/
43) of cases associated with a positive CtBP1 staining whereas
only 15.4% (2/13) cases of Brca1 loss associated with a
negative CtBP1 staining (P¼0.0007, Figure 4b). The inverse
correlation of Brca1 and CtBP1 suggests an important role of
CtBP1 in transcriptional control of Brca1 in melanoma.
Consistently, the DNA-damage surrogate marker, pH2AX,
staining in the melanoma tissue array was inversely correlated
with Brca1 expression (P¼ 0.024, Figure 4c).
Our results provided a potential mechanistic link between
CtBP1 overexpression and melanoma genomic instability.
Therefore, we were prompted to investigate the role of CtBP1
in transcriptional control of Brca1 in samples from melanoma
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Figure 3. Transcriptional regulation of Brca1 (breast cancer susceptibility gene 1) gene by Carboxyl-terminal binding protein 1 (CtBP1) in melanoma cells. (a)
CtBP1 binding to the Brca1 promoter in A375 cells. **Po0.01 versus IgG. (b) CtBP1 knockdown (siCtBP1-1 and siCtBP1-2) in A375 cells increased Brca1 mRNA.
*Po0.05. (c) CtBP1 knockdown increases mitomycin C (MMC)-induced DNA-repair foci formation. A375 cells were transfected with small interfering RNAs
(siRNAs) for 48 hours and treated with 10 ng ml1 MMC for 24 hours before being subjected to DNA-repair Brca1-foci staining. Bar¼ 5mm. (d) Brca1 expression
was upregulated by in vivo delivery of siRNAs to knockdown CtBP1 in A375 xenografts for 2 weeks. (e) CtBP1 knockdown decreases DNA breaks. A375 cells were
isolated from xenografts and assayed for DNA breaks. Arrows point to cells with accumulated DNA breaks (comets). Bar¼ 20mm.
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patients. Melanoma cells isolated from three subcutaneous
melanoma metastasis cases were used in the CtBP1 knock-
down experiments. No Brca1 upregulation was detected in
MB1547 upon CtBP1 knockdown (Figure 4d); however,
significant increases of Brca1 mRNA was observed in
MB1589 (Figure 4e) and MB1823 (data not shown) when
CtBP1 was knocked down. In light of our findings that siRNA
knockdown of CtBP1 increases Brca1 expression and function
to repair DNA damage, these data suggest that blocking CtBP1
activity could be a potential strategy for preventing melanoma
progression by increasing repair of DNA damage and thus
genome stability.
DISCUSSION
CtBP1 has been functionally linked to proliferation, antiapop-
tosis, and epithelial–mesenchymal transition from in vitro
studies (Grooteclaes et al., 2003; Zhang et al., 2003; Mroz
et al., 2008). Our recent study in head and neck squamous
cell carcinoma found CtBP1 overexpression starting at the
hyperplasia stage and revealed an additional suppressive role
of CtBP1 on Brca1, thus providing a link to a defect in
DNA-damage repair and genome instability (Deng et al.,
2010). Here, we have demonstrated transcriptional regula-
tion of Brca1 by CtBP1 in melanoma cells. Furthermore, Brca1
loss was detected in human melanoma samples and correlated
with increased CtBP1 staining in these lesions. Similar to the
results obtained using WM852 and A375 melanoma cell lines,
CtBP1 knockdown upregulated Brca1 expression in two of
three melanoma cases. These findings support the notion that
CtBP1 plays an important role during melanoma development
by dampening DNA-damage repair. Our study shows that
CtBP1 overexpression and Brca1 loss are detected in both
melanomas and epithelial-originated cancers, e.g., head and
neck cancers and breast cancers, suggesting that these
molecular alterations are common in carcinogenesis.
Studies on the pathogenesis of melanoma have focused
mainly on genetic alterations. Some studies have suggested an
increase in malignant melanoma, both cutaneous and ocular,
in families with mutations in Brca2 (BCLC, 1999). This was not
confirmed in a smaller Dutch study (van Asperen et al., 2005),
and studies of unselected uveal melanoma cases have not
shown excess rates of Brca2 mutations (Hearle et al., 2003).
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A recent study also reported an absence of founder Brca1 and
Brca2 mutations in cutaneous malignant melanoma (Kadouri
et al., 2009). This paradox may be explained by the CtBP1-
mediated transcriptional control of these and other tumor-
suppressor genes. In fact, we have detected loss of p16INK4a
and Brca1 protein in human melanoma tissues in an inverse
correlation with CtBP1 levels. As a well-known tumor
suppressor of melanoma (Krimpenfort et al., 2001; Yang
et al., 2001; Monahan et al., 2010), p16INK4a has been
shown to be downregulated in cutaneous melanoma
(Hussussian et al., 1994; Jonsson et al., 2010). Our study
suggests that CtBP1 overexpression may represent a critical
regulator of p16INK4a levels in melanoma. In contrast, no
Brca1 alternation has been reported in melanoma despite the
association between melanoma and breast cancer reported in
the literature (Larson et al., 2007; Seltzer and Leachman,
2008). Our study represents, to our knowledge, previously
unreported identification of Brca1 loss in melanoma. Brca1
plays an important function in DNA-damage repair,
maintaining genome stability (Shen et al., 1998; D’Andrea
and Grompe, 2003; Mueller and Roskelley, 2003).
Overexpression of CtBP1 in human melanoma lesions
appears to decrease the expression and function of the
Brca1 gene, thus contributing to genomic instability during
melanoma initiation. MC1R, MMP-8, and b-catenin have
been added to the list of tumor suppressors for melanoma
(Box et al., 2001; Palavalli et al., 2009; Arozarena et al.,
2011). Future studies will address whether CtBP1 affects these
pathways in the context of melanoma development.
A previous study (Poser et al., 2002) has suggested that loss
of CtBP1 mRNA expression in melanoma samples results in
upregulation of MIA (melanoma inhibitory activity). In
contrast, we have found that CtBP1 protein expression is
positive in a large percentage of human malignant melanoma
lesions (43/56 cases) and several melanoma cell lines
(Supplementary Figure S1 online), suggesting that
translational or posttranslational control of CtBP1 may be
affected in melanoma. Previously, tumor suppressors such as
HIPK2 and Arf have been identified to regulate CtBP1 protein
stability (Zhang et al., 2003; Paliwal et al., 2006). Another
potential regulator of CtBP1 protein might be melanoma-
associated miRNAs (Pillai et al., 2007). Improper expression of
miRNA genes is seen in both benign and malignant cancers.
miRNA expression profiles can be used to classify solid
tumors (Lu et al., 2005), and a previous study has shown
that miRNA expression differs between melanoma cell
lines (Gaur et al., 2007). All these can lead to CtBP1
overexpression in melanoma. The resultant downregulation
of Brca1 and its subsequent defect in DNA-damage
repair will increase genome instability, whereas the
loss of p16INK4a would release tight control of CDKs,
resulting in cell cycle progression and deregulation of the
oxidative stress response in melanomas (Jenkins et al., 2011).
Knocking down the central regulator CtBP1 restored
the expression and function of p16INK4a and Brca1 genes.
We speculate that downregulating CtBP1 activity might be
of preventative or therapeutic value for human melanoma
treatment.
Taken together, our study highlighted the importance
of the transcriptional corepressor CtBP1 in melanoma devel-
opment by the suppression of tumor-suppressor genes
such as Brca1 and p16INK4a. Further study will aim at
testing the prognostic value of CtBP1 in human melanoma
as well as addressing the possibility of targeting CtBP1 as a
melanoma therapy, either by itself or in combination with
other current treatment.
MATERIALS AND METHODS
Immunofluorescence and immunohistochemistry
Consecutive slides of human melanoma array ME1003 were
purchased from US Biomax (Rockville, MD). These arrays are made
with tissue blocks collected within 5 years specifically for making
tissue microarrays. All tissue samples were collected under The
Health Insurance Portability and Accountability Act of 1996
(HIPAA)-approved protocols; donors were informed the complete
protocol and they gave their consent. After surgery, tissue samples
were put into formalin. This process was performedo10 minutes after
surgery and before fixation. Every tissue spot on array slide was
individually examined by pathologists certified according to the
World Health Organization (WHO) published standards of diagnosis,
classification, and pathological grade. Every 10th section of the
tissue array was stained with hematoxylin and eosin and reviewed
by two board-certified pathologists to confirm that the pathology
diagnosis was current and matched to the adjacent serial sections.
Pathological reconfirmation report was generated and a digital image
was captured.
Specificity of the anti-CtBP1 antibody (Millipore, Billerica, MA) was
evaluated by immunofluorescence assay using the CtBP1 / versus
the CtBP1-postive mouse embryonic fibroblasts (Grooteclaes et al.,
2003) before being used in human melanoma tissue arrays. To assess
the correlation between CtBP1 and the tumor suppressors p16INK4a
and Brca1, antibodies against p16INK4a (Santa Cruz Biotechnology,
Santa Cruz, CA), Brca1 (Santa Cruz Biotechnology), and CtBP1
(Millipore) were used to stain consecutive tissue sections, as we
previously described (Bornstein et al., 2009). The Vector Red Alkaline
Phosphatase Substrate Kit 1 (Vector Laboratories, Burlingame, CA)
was used in the immunohistochemical development. Evaluation of
CtBP1, Brca1, and p16INK4a staining of human melanoma samples
was assessed by two independent investigators using the methods
described previously (Bornstein et al., 2009). The Fisher’s exact test
was used to calculate the P-value for the correlation of CtBP1
expression with Brca1 and p16INK4a levels in melanoma samples.
pH2AX (Cell Signaling, Danvers, MA) staining was also performed as
an indicator of DNA damage in melanoma samples.
Cell culture and assays
Human epidermal melanocytes were purchased from Invitrogen
(Carlsbad, CA). Melanoma samples were collected according to the
Declaration of Helsinki Principles and all patients gave written
informed consent under the Colorado Multiple Institutional Review
Board (COMIRB)–approved protocol. Isolated melanoma cells were
cultured briefly for CtBP1 knockdown experiments. Melanoma cell
lines were maintained in RPMI-1640 with 10% fetal bovine serum at
37 1C in a humidified atmosphere of 5% CO2. Melanoma cells were
transfected using Lipofectamine 2000, Invitrogen (Grand Island, NY)
with 100 nM scrambled siRNA (control) or siCtBP1 (Zhang et al.,
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2003; Bergman et al., 2009) and incubated at 37 1C for 48 hours.
p16INK4a expression was detected by immunofluorescence staining
using a p16INK4a antibody (Santa Cruz Biotechnology) (Hoot et al.,
2008). MMC-induced DNA-repair foci formation was assayed using a
Brca1 antibody (Santa Cruz Biotechnology) as we previously
described (Bornstein et al., 2009). DNA breaks were detected using
the comet assay (Tyagi et al., 2011). For the cell growth assay, cells
were collected by trypsinization and counted using hemocytometer.
For in vivo CtBP1 knockdown (Hobel and Aigner, 2010), 100ml of
HEPES containing polyethylenimine mixed with 1mM scrambled
siRNA (control) or siRNAs targeting CtBP1 (siCtBP1-1 and siCtBP1-
2) was injected to the A375 xenografts three times per week for 2
weeks after the tumors were established in nude mice. Cells were
harvested to assay their CtBP1 and Brca1 expression using
quantitative real-time reverse-transcriptase–PCR (qRT–PCR) and
their DNA breaks using the comet assay.
ChIP and qRT–PCR
ChIP assays were performed on melanoma cells using an anti-CtBP1
antibody as described previously (Zhang et al., 2006). Primer sets
encompassing p16INK4a and Brca1 promoters were used to amplify
ChIP samples in qRT–PCR: 50-AGAGCCCCCTCCGACCCTGT-30 and
50-GGCGTCCCCTTGCCTGGAA-30 for p16INK4a; 50-CAATCAGAG
GATGGGAGGGACAGA-30 and 50-CAGAGCCCCGAGAGACGCT
TG-30 for Brca1 gene; and 50-CCACTGCGTCCAGCCATTCTTGT-30
and 50-CTTGAGAGGCCAAGGGAGGGTAGA-30 for nontarget. Total
RNA was isolated using TRIzol (Invitrogen) and qRT–PCR was
performed as previously described (Zhang et al., 2006). An 18S
probe was used as an internal control. The relative RNA expression
levels were determined by normalizing to internal controls; values
were calculated using the comparative Ct method. Samples were
assayed in triplicate for each experiment and at least two independent
experiments were performed. Data are presented as mean±SEM
(n¼ 3) from a representative experiment.
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